Laboratory for Early Markers Of Neurodegeneration
R&D > Laboratories > Laboratory for Early Markers Of Neurodegeneration – Prof. Anat Mirelman
Our Vision
Our mission is to better understand the pathological process of ageing and neurological diseases and discover new markers of neurodegeneration. We explore clinical, biological and neuronal markers using different tools such as neural-imaging (e.g., MRI, fMRI, EEG and fNIRS) and body fixed sensors with the aim of identifying sensitive measures that can quantify progression and predict neurodegeneration in prodromal and healthy individuals and populations at risk due of genetic mutations.
Contact Us
Primary Investigators
Prof. Anat Mirelman, Lab PI
Dept of Neurology, Sackler School of Medicine ; Sagol School of Neuroscience
Phone: +972-3-6973014 / 3960
Email: Lemon@tlvmc.gov.il
Ora Assais, Lab administrative manager
Phone: +972-3-6973014 / 3960
Email: Lemon@tlvmc.gov.il
Address
Rishonim building
5th floor 6 weizmann st., Tel Aviv
Research
Collaborative project with Biogen aiming to identify prodromal markers of Parkinson’s disease. The study included healthy LRRK2 and GBA mutation carriers, who are individuals at risk for developing Parkinson’s disease. The longitudinal study explored clinical, biological, imaging and digital data
PPMI is a landmark multi-site study collaborating with partners around the world to create a robust open-access data set and biosample library to speed scientific breakthroughs and new treatments. The study was initiated and funded by Michael J Fox Foundation.
As part of PPMI, Prof. Mirelman leads the digital mobility efforts, exploring the potential and sensitivity of these technologies in identifying early disease.
Sleep-related symptoms are one of the most common non-motor symptoms in Parkinson’s disease (PD). They have been associated with increased risk of neurodegeneration, cognitive decline, and reduced quality of life. In this study, we are using novel wireless skin electrodes and wearable sensors to provide a “home-based sleep lab test”. The novel electrodes are printed on a thin and soft sticker, and are placed conveniently on the face of the person to enable physiologic recordings (EEG, EOG, EMG) over multiple nights in the home environment. The study aims to evaluate the frequency and severity of sleep abnormalities in patients with PD. The study is funded by the US Department of Defense.
Traditional neuroimaging is limited as it is done while the person is lying down, motionless in the scanner. In recent years, developments in imaging techniques such as Electroenchepalogram (EEG) and Functional Near-Infrared Spectroscopy (fNIRS) have paved the way to explore neural function and activation during actual performance. Using these techniques we aim to understand neural dysfunction in different diseases and compensation activation in the face of disease.
Postoperative cognitive dysfunction (POCD) and delirium, are unfortunately common, affecting 1.5–54.9% of surgical patients. A recent consensus statement defined postoperative Neuro Cognitive Decline (NCD) as a spectrum ranging from delirium, delayed neurocognitive recovery and POCD. The exact pathophysiology of neurocognitive dysfunction is not clear. This presents a challenge in identifying risk subjects for POCD. In this study we evaluate the predictive value of a novel motor-cognitive test in predicting delirium. This study is a collaborative project with the Surgical, Anestesia and critical care units.
Gallery
Our Team
Current Staff
Researchers
- Anat Mirelman, PhD
- Inbal Maidan, PhD
- Amgad Droby, PhD
- Avner Thaler, MD, PhD
- Nurit Omer, MD
- Ora Assais
- Batsheva Cohen, RN
- Liat Yachimovich
- Shira Paz
- Shani Oz
- Roni Hacam
- Daniel Postti
Doctoral Student
- Tal Kozlovski
- Tamara Schechter-Margalit
- Andrew Dagay
- Ori Peleg
- Zoya Katzir
MSc Student
- Shira Paz
- Rotem Saban
- Shlomit Katzav
- Yael Ezra
- Sarah Leviashvili
- Rom Harel
- Rawan Silbak
Past Staff
- Yevgenia Rosenblum
- Shiran Sustak
- Noam Ben Benyamin
- Mei Tal Litvak
- Mor Yam
- Shani Danziger-Schragenheim
Current funding
Highlighted Publications
Using Technology to Reshape Clinical Care and Research in Parkinson’s Disease. J Parkinsons Dis. Mirelman A, Dorsey ER, Brundin P, Bloem BR
2021;11(s1):S1-S3. doi: 10.3233/JPD-219002. PMID: 33612498.
Mutations in GBA and LRRK2 Are Not Associated with Increased Inflammatory Markers. J Parkinsons Dis.
Thaler A, Omer N, Giladi N, Gurevich T, Bar-Shira A, Gana-Weisz M, Goldstein O, Kestenbaum M, Shirvan JC, Cedarbaum JM, Orr-Urtreger A, Regev K, Shenhar- Tsarfaty S, Mirelman A
2021;11(3):1285-1296. doi: 10.3233/JPD-212624. PMID: 33998549; PMCID: PMC8461659.
Biochemical markers for severity and risk in GBA and LRRK2 Parkinson’s disease.
Thaler A, Omer N, Giladi N, Gurevich T, Bar-Shira A, Gana-Weisz M, Goldstein O, Kestenbaum M, Cedarbaum JM, Orr-Urtreger A, Shenhar-Tsarfaty S, Mirelman A.
J Neurol. 2021 Apr;268(4):1517-1525. doi: 10.1007/s00415-020-10325-4. Epub 2021. Jan 3. PMID: 33388928
More Publications >>
A multimodal approach using TMS and EEG reveals neurophysiological changes in Parkinson’s disease.
Maidan I, Zifman N, Hausdorff JM, Giladi N, Levy-Lamdan O, Mirelman A.
Parkinsonism Relat Disord. 2021;89:28-33.
Whole brain and deep gray matter structure segmentation: Quantitative comparison between MPRAGE and MP2RAGE sequences . Droby A, Thaler A, Giladi N, Hutchison RM, Mirelman A, Ben Bashat D, Artzi M. PLoS One. 2021 Aug 6; 16(8):e0254597. doi: 10.1371/ journal.pone.0254597. PMID: 34358242; PMCID: PMC8345829.
Detecting Sensitive Mobility Features for Parkinson’s disease stages via Machine learning
Mirelman A, Ben Or Frank M, Melamed M, Granovsky L, Nieuwboer A, Rochester L, Del Din S, Avanzino L, Pelosin E, Bloem BR, Della Croce U, Cereatti A, Bonato P, Camicioli R, Ellis T, Hamilton JL, Hass CJ, Almeida QJ, Inbal M, Thaler A, Shirvan J, Cedarbaum JM, Giladi N, Hausdorff JM.
Mov Disord. 2021
Schejter-Margalit T, Kizony R, Shirvan J, Cedarbaum JM, Bregman N, Thaler A, Giladi N, Mirelman A.
Parkinson and Relat Disord. 2021
Droby A, El Mendili MM, Giladi N, Hausdorff JM, Maidan I, Mirelman A.
Gait Posture. 2021
Whole brain and deep gray matter structure segmentation: Quantitative comparison between MPRAGE and MP2RAGE sequences . Droby A, Thaler A, Giladi N, Hutchison RM, Mirelman A, Ben Bashat D, Artzi M. PLoS One. 2021 Aug 6; 16(8):e0254597. doi: 10.1371/ journal.pone.0254597. PMID: 34358242; PMCID: PMC8345829.
Maidan I, Hacham R, Galperin I, Giladi N, Holtzer R, Hausdorff JM, Mirelman
Neurology. 2021
Glucocerebrosidase activity in not associated with Parkinson;s disease risk or severity
Omer N, Giladi N, Gurevich T, Bar-Shira A, Gana-Weisz M, Glinka T, Goldstein
O, Kestenbaum M, Cedarbaum JM, Mabrouk OS, Fraser KB, Shirvan JC, Orr-Urtreger A, Mirelman A, Thaler A.
Mov Disord. 2022
Event-related oscillations differentiate between cognitive, motor and visual impairments
Rosenblum Y, Shiner T, Bregman N, Fahoum F, Giladi N, Maidan I, Mirelman A.
J Neurol. 2022
